Do elevated thyroid peroxidase antibodies indicate thyroid autoimmunity and higher risk of thyroid dysfunction?

Thyroid peroxidase antibodies (TPOAb) serve as a critical diagnostic and prognostic marker for autoimmune thyroid disorders, identifying individuals at high risk for progressive metabolic dysfunction.

Clinical evidence and risk of progression

• Diagnostic accuracy: Elevated TPOAb exhibits a diagnostic sensitivity exceeding 95% for Hashimoto's thyroiditis and a specificity of 90% to 100%. It is also elevated in 53% to 87% of individuals with Graves' disease.
• Progression risk: In euthyroid individuals, TPOAb positivity represents a preclinical phase of thyroid failure. Data show an annual progression rate to hypothyroidism of approximately 2.1% in euthyroid women, translating to a 10% to 20% cumulative risk over a decade.
• Risk modifiers: Progression accelerates when TPOAb titers exceed 187 IU/mL or when baseline TSH is high-normal. In pregnant or preconception women, the risk is highly pronounced, with 7% to 7.4% of euthyroid, TPOAb-positive individuals progressing to hypothyroidism within one year.

Pathogenic mechanisms

• Antibody synthesis: TPO antibodies are produced directly by thyroid-infiltrating lymphocytes, meaning circulating titers closely reflect the density of localized lymphocytic infiltration.
• Thyrocyte injury: Rather than acting as passive biomarkers, TPO antibodies actively drive tissue damage. They bind to follicular cells and initiate follicular destruction via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
• Functional decline: Accumulated, antibody-driven destruction of thyroid follicular cells and the subsequent loss of functional thyroid tissue ultimately culminate in progressive thyroid hormone deficiency.

Bottom line

• Elevated TPOAb is a highly specific marker and active pathogenic driver of thyroid autoimmunity, predisposing euthyroid individuals to a 2% to 7.4% annual risk of progressing to hypothyroidism and requiring structured clinical monitoring.